AIM To assess the pharmacokinetic of
intracranially administered
cisplatin delivered from sustained releasing polymers
for treatment of experimental gliomas in rats. METHODS C6 glioma cells were injected
intracranially into rats, and the polymer loaded with
cisplatin (1 mg·m -2 ) was implanted at the site of tumor on d 7 after C6 glioma cells were injected, meanwhile cisplatin solution (50 mg·m -2 ) was injected ip in the systemic administration group. At different times, the rats were sacrificed to collect tumor, brain tissue, blood and kidney samples to measure the platinum concentration by flameless atomic absorption spectroscopy (FASS). RESULTS The platinum level at tumor center in rats receiving intratumoral injection of cisplatin loaded polymer was compared with that in rats receiving intraperitoneal administration of high doses of cisplatin solution. The platinum level at tumor center following local injection was 2 to 50 times higher than that following systemic injection. Platinum concentration in blood and kidney after intratumoral administration was only 1.6%-10% and 0.45%-14% of that after systemic administration repectively. Biodegradable sustained releasing polymers can safely deliver cisplatin intracranially. CONCLUSION Intracranially administered biodegradable sustained releasing cisplatin polymer could safely deliver higher concentration of platinum at tumor center than systemic administration of cisplatin solution.